Bio-Path Holdings, Inc. Stock price
Is Bio-Path Holdings, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Bio-Path Holdings, Inc. Stock Analysis
Analyst Opinions
7 Analysts have issued a Bio-Path Holdings, Inc. forecast:
Analyst Opinions
7 Analysts have issued a Bio-Path Holdings, Inc. forecast:
Don't miss a Thing! We will send you all news about Bio-Path Holdings, Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
| Head office | United States |
| CEO | Mr. Grover |
| Employees | 10 |
| Founded | 2007 |
| Website | www.biopathholdings.com |


